dAdo is known to be toxic to both proliferating and resting lymphocytes that lack adenosine deaminase (ADA) activity. We now show that human monocytes are also highly sensitive in vicro to nM concentrations of dAdo plus the ADA inhibitor deoxycoformycin. and to the ADA-resistant analog CdA. The dose-and cimedependent toxicity of dAdo or CdA to monocytes is blocked by deoxycytidine, implicating deoxycytidine kinase in the formation of toxic dAdo or CdA nucleotides. Monocytes exposed to dAdo plus deoxycoformycin, or to CdA accumulate massive DNA damage detectable within 1 hour. The accumulation of DNA strand breaks in lymphocytes stimulates the lethal consumption of NAD and ATP for poly ( AD?-ribose) synthesis. However, monocytes lack the poly(ADP-ribose) polymerase enzyme and therefore show no significant NAD or AT? depletion uncil cell viability declines (12 hr).
and Ernest Ecurler. Research Institute of Scripps Clinic, La Jolla, CA USA. U n l i k e o t h e r n u c l e o s i d e a n t i -m e t a b o l i t e s , 2 -chlorodeoxyadenosine is selectively toxic at nanomolnr concentrations to h u m a n lymphocytes and monocytes.
In susceptible cells, the drug causes a dose-and time-dependent accumulation of DNA strand breaks, with resultant activation of poly(ADP-ribose) polymerase. Furthermore, the actions of 2 -chlorodeoxyadenosine are elltirely indtpendenc of replicative DXA s y n t h e s i s .
F o r t h i s r e a s o n , w e r e a s o n e d c h a t 2 -chlorodeoxyadenosine wouid rzpresent a useful aeent for the treatment of slowly replicating lymphoid malignancies, and for the therapy of chronic autoimmune diseases. In the prasent study. 2-chlorodeoxyadenosine was administ<red to 18 parients with advanced chronic lymp!iozytic leukemia, 4 o f who~n had c~n~u r r o n t autoimmune he~nolytic anemia. An overall response rut* of '14% was achieved. Only minor and reversible bone marrow suppression occurred during treatment, indicating a high degree of lymphocyte selectivity. Moreover, 3 of the 4 patients with autoimunr hemolytic anemia h&d complete resolution of hemolysis. Three paiients with hairy cell leukemia also received 2 -clllorodeoxyadenosine therapy. Tjro of the patients achieved .clii~ic~i remission ~E t e r one course of the drug. These results demonstrate that 2-cl~loroduosyadanosine is a safe and potent anti-lymphocyte and irrmunosuppressive aqent. Furtiler trials a f the drug in autoi~ni~lrina and ly~nptioproliferative diseases are warranted. 2',3'-dideoxyadenosine (ddA) has activity against the human immunodeficiency virus-1 (HIV) , but is rapidly catabolized by human T cells, even when adenosine deaminase is inhibited by deoxycoformycin. To overcome this problem, we developed a simple method to synthesize the 2-fluoro-, 2-chloro-, and 2-bromoderivatives of ddA. The isolated 2-halo-ddA derivacives were not deaminated significantly by cultured T lymphoblasts, which converted the dideoxynucleosides to the respective 5'-monophosphate, 5'-diphosphace, and 5'-criphosphate mecabolires. At concentrations lower than those producing cytocoxicity in uninfected cells (3-10 pM), the 2-halo-ddA derivatives inhibited the cytopathic effects of HIV toward T lymphoblasts, and retarded viral replication. Experiments with a deoxycytidine kinase deficient mutant CEM T cell line showed that this enzyme was necessary for the phosphorylatian and anti-HIV activity of the 2-halo-ddA derivatives. Thus, the 2-halo-ddA congeners, in contrast to ddA itself, are not degraded by T lymphocytes, and represent promising compounds for in vivo chemotherapy of HIV infection. College. Tokyo, Japan Before World War 11, the incidence of gout had been low in Taiwan and has begun to increase only after the war, probably reflecting the change of the diet due to the economical development and improved standards of living in the country. Since our clinic was established in 1983, we have seen a total number of approximately 4.000 patients with gout. The diagnosis of gout was made according to the criteria proposed by the American Rheumatism Association. For every gouty patient visiting our clinic for the first time, the serum urate concentration and the amount of urate in the 24-hour urine were examined. The serum urate concentration was checked at 2 months intervals in order to monitor the effects of drugs. In addition to these tests, general data including hematological findings, serum biochemistry information, urine analysis, renal function, chest X-ray examincation and EKG were obtained every one year for each patient. The data from these 4.000 patients have been accumulated and submitted to the analysis by a computer. Based on such clinical and laboratory observations and the results obtained by the analysis, we discuss about characteristic features of gout in people in Taiwan. A retrospective study of 49 patients with/or suspected for an immune disease was done to enable a comparision between levels of purine en-zymes in mononuclear cells and some frequently used markers of immune function. A new observation was the finding of correlation between low ecto-S'nucleotidase activity and decreased T lymphocyte function measured as decreased lymphocyte proliferation after mito-and antigenic stimulation in vitro. In this study we did not find correlation between the activity of ecto-S'nucleotidase and the other investigated markers of immune function (lympfocyte count, lymphocyte subpopulations, concentration of immunoglobulines in serum and lymphocyte proliferation after mito-and antigenic stimulation in vitro). The activities of adenosine deaminase and purine nucleoside phosphherylase in mononuclear cells were also measured. In this group of patients no correlation was find between the activities of these enzymes and the investigated markers of immune function. The activity of ecto-S'nucleotidase on monouclear cells isolated from freshly drawn venous blood change during culture. The measured ecto-S'nucleotidase activity on mononuclear cells was much higher than the activity estimated from lymphocytes and monocytes when cultivated separately. The average ecto-5' nucleotidase activity on mononuclear cells after 2 days culture was 86.8 m o l e product developed/h/lo6 cells (u/106 cells) whereas the activity before culture was 22.0 IJ/106 cells. After the same period in culture the activity in lymphocytes and monocytes cultivated separately was 21.2 u/106 cells and 126.2 respectively. These results indicate that the activity of ecto-S'nucleotidase on cultured mononuclear cells is regulated by interactions between lymphocytes and monocytes.
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